| oxaliplatin / Generic mfg. |
NCT06206096: PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC |
|
|
| Recruiting | 2 | 40 | RoW | oxaliplatin+capecitabine+bevacizumab+PD-1 antibody | Chinese PLA General Hospital | Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma | 12/24 | 12/25 | | |
HNGC-004, NCT03939962: Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | SHR1210 combined with FOLFOX | Henan Cancer Hospital | Gastric Cancer | 05/21 | 05/24 | | |
NCT03135652: Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation |
|
|
| Withdrawn | 2 | 120 | RoW | adjuvant SBRT, radiotherapy, Chemotherapy, neoadjuvant chemotherapy and adjuvant chemotherapy | Wuhan Union Hospital, China | Radiotherapy, Colorectal Cancer, Liver Metastases | 06/21 | 06/23 | | |
| Completed | 2 | 218 | Europe | Bevacizumab, Irinotecan, Oxaliplatin, L-Leucovorin, 5-fluorouracil, Atezolizumab | Gruppo Oncologico del Nord-Ovest, Roche Pharma AG | Metastatic Colorectal Cancer | 06/21 | 08/23 | | |
2020-004636-25: Incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain in the adjuvant or metastatic setting. |
|
|
| Not yet recruiting | 2 | 49 | Europe | Lonsurf, oxaliplatin, Tablet, Solution for infusion, Lonsurf, oxaliplatin | GERCOR, Servier | colorectal or oesogastric adenocarcinoma, colorectal or oesogastric adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
NCT04797923: A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination |
|
|
| Recruiting | 2 | 43 | RoW | 1. Treatment: IP chemotherapy + Systemic chemotherapy, 2. Response evaluation after 4 cycles of IP + systemic chemotherapy | Gangnam Severance Hospital | Advanced Gastric Cancer, Peritoneal Carcinomatosis | 06/21 | 12/21 | | |
NCT03791905: PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 216 | RoW | Paclitaxel, Taxol, Cisplatin, DDP, Oxaliplatin, OXA, 5-FU, Fluorouracil, Leucovorin, CF, Intensity-modulated radiotherapy, IMRT, PET, PET-CT | Mian XI | Neoplasm, Esophageal, Squamous Cell Carcinoma | 07/21 | 12/23 | | |
2021-001206-29: Study of Short-course radiotherapy followed by chemotherapy as treatment pre surgery for locally advanced rectal cancer. STUDIO DI RADIOTERAPIA SHORT-COURSE SEGUITA DA CHEMIOTERAPIA COME TRATTAMENTO PRECEDENTE ALL’INTERVENTO CHIRURGICO PER IL TUMORE DEL RETTO LOCALMENTE AVANZATO. |
|
|
| Not yet recruiting | 2 | 63 | Europe | Irinotecan, [Irinotecan], Concentrate and solvent for concentrate for solution for infusion | Fondazione GONO, Fondazione GONO | Locally advanced rectal cancer TUMORE DEL RETTO LOCALMENTE AVANZATO, Rectal cancer amenable to curative resection. Tumore del retto operabile, Diseases [C] - Cancer [C04] | | | | |
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen |
|
|
| Not yet recruiting | 2 | 25 | Europe | Retifanlimab, INCMGA00012, Solution for infusion | Academic Medical Center, Incyte | Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04] | | | | |
FDZL-PFG, NCT04510064: PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Camrelizumab plus mFLOT regimen, R0 surgery | Fudan University | Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma | 08/21 | 08/22 | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
NCT04136600: EGFR Monoclonal Antibody for Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | EGFR antibody and Chemotherapy, Chemotherapy | Shanghai Changzheng Hospital | Gastric Cancer, Cetuximab, Nimotuzumab | 08/21 | 12/21 | | |
2019-004397-26: Immunotherapy in combination with chemotherapy with intrahepatic administration of oxaliplatin for patients with multiple liver metastasis from colorectal cancer. Immunterapi i kombination med kemoterapi med oxaliplatin direkte til leveren til patienter med multiple metastaser fra tarmkræft |
|
|
| Not yet recruiting | 2 | 30 | Europe | Oxaliplatin, 5-FLUOROURACIL, Calcium Folinate (Folinic Acid), Concentrate for solution for infusion, Solution for infusion, Solution for injection/infusion, Opdivo, Yervoy | Department of Oncology, Herlev & Gentofte Hospital, Department of Oncology, Herlev & Gentofte Hospital, Danish Cancer Society | Liver metastasis from colorectal cancer, Liver metastasis from colorectal cancer, Diseases [C] - Cancer [C04] | | | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
2021-001353-31: SEQUENTIAL GEMCITABINE PLUS NABPACLITAXEL (GEMBRAX) TREATMENT FOLLOWED BY FOLFIRINOX or FOLFIRINOX IN PATIENTS TREATED FOR FIRST LINE METASTATIC PANCREATIC CANCER Traitement séquentiel par gemcitabine plus nab-paclitaxel (GEMBRAX) suivi de FOLFIRINOX ou par FOLFIRINOX seul chez des patients traités en 1ère ligne métastatique d’un cancer du pancréas |
|
|
| Not yet recruiting | 2 | 210 | Europe | | Institut régional du Cancer de Montpellier, ICM | METASTATIC ADENOCARCINOMA OF PANCREATIC Adénocarcinome métastatique du pancréas, Pancreas cancer Cancer du pancréas, Diseases [C] - Cancer [C04] | | | | |
NCT02017704: Chemoradiation or Brachytherapy for Rectal Cancer |
|
|
| Completed | 2 | 9 | US | Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), Xeloda, IMRT (intensity modulated radiation therapy), FOLFOX6, Oxaliplatin, Leucovorin, 5 Fluorouracil, Surgery | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nucletron | Rectal Cancer | 09/21 | 01/23 | | |
NCT04098796: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Anti-PD-1 antibody, XELOX | China Medical University, China | Gastric or Gastroesophageal Junction Adenocarcinoma, AFP | 09/21 | 09/21 | | |
NCT03484221: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil, Short-Course Radiation Therapy(5Gy*5), XELOX, Capecitabine | China Medical University, China | Rectal Neoplasms, Drug Therapy, Radiation | 10/21 | 04/22 | | |
NCT03484195: Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil | China Medical University, China | Colonic Neoplasms, Drug Therapy | 10/21 | 10/21 | | |
NCT03487939: Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOXIRI, Irinotecan, Oxaliplatin, 5-Fluorouracil | China Medical University, China | Colorectal Neoplasms, Drug Therapy | 10/21 | 10/21 | | |
2021-000553-40: Study of NIS793 and other novel investigational combinations with SOC anti-cancer therapy for the second line treatment of mCRC Az NIS793 vizsgálata és egyéb új vizsgálati készítmények hagyományos rákellenes kezelésekkel való kombinációja az áttétes kolorektális rák (mCRC) másodvonalbeli kezeléseként |
|
|
| Ongoing | 2 | 190 | Europe | 5-Fluorouracil, oxaliplatin, leucovorin, irinotecan, bevacizumab, NIS793, Concentrate for solution for infusion, Powder for solution for infusion | Novartis Pharma AG, Novartis Pharma AG | metastatic colorectal cancer (mCRC), colorectal cancer, Diseases [C] - Cancer [C04] | | | | |
| Not yet recruiting | 2 | 66 | NA | cTACE-HAIC, OXRI | Beijing Cancer Hospital | Transarterial Chemoembolization, Hepatocellular Carcinoma | 10/21 | 10/22 | | |
2020-002715-21: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study |
|
|
| Not yet recruiting | 2 | 80 | Europe | Atezolizumab, IMM-101, L01XC32, Concentrate for solution for infusion, Suspension for injection, Tecentriq (R) | AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd, Immodulon Therapeutics Ltd. | Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study), patients with stage III colon or rectum cancer who are ineligible or refuse oxaliplatin-based chemotherape after surgical removal of the tumor (main study) oder the surgery is planned (sub-study), Diseases [C] - Cancer [C04] | | | | |
CASSANDRA, NCT04793932: Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG ( TRIAL) |
|
|
| Recruiting | 2 | 261 | Europe | PAXG, mFOLFIRINOX, short-course chemotherapy, long-course chemotherapy | Associazione Italiana per lo Studio del Pancreas, High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Pancreas Ductal Adenocarcinoma | 11/21 | 11/23 | | |
IRIGA, NCT04442984: FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) |
|
|
| Recruiting | 2 | 326 | RoW | Irinotecan, Oxaliplatin, 5-FU, Leucovorin | Blokhin's Russian Cancer Research Center | Gastric Carcinoma Stage IV, Esophagogastric Junction Adenocarcinoma Stage IV | 11/21 | 11/24 | | |
nITRo, NCT03528785: A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 67 | Europe | Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid | Centro Ricerche Cliniche di Verona | Pancreatic Adenocarcinoma | 11/21 | 11/22 | | |
NCT01191697: CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer |
|
|
| Active, not recruiting | 2 | 37 | US | bevacizumab, Avastin, trastuzumab, Herceptin, oxaliplatin, capecitabine, xeloda | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc. | Esophageal Cancer, Gastric Cancer | 12/21 | 07/24 | | |
|
NCT02555358: Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study |
|
|
| Completed | 2 | 300 | RoW | docetaxel,0xaliplatin,capecitabine, AISU,AIHENG,AIBIN, oxaliplatin,capecitabine, AIHENG,AIBIN | Qun Zhao, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer | 12/21 | 06/22 | | |
NCT04694404: Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | S-1,Oxaliplatin | Aiping Zhou | S-1 Plus Oxaliplatin | 12/21 | 12/22 | | |
ChiCTR1800019831: Clinical study for cetuximab combined with capecitabine maintenance therapy after first-line cetuximab combined with FOLFIRI/mFOLFOX6 chemotherapy for RAS wild-type advanced left colorectal cancer |
|
|
| Recruiting | 2 | 136 | | Cetuximab combined with capecitabine ;capecitabine alone | Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University, own expense | left colorectal cancer | | | | |
NCT04121039: Study of the Apatinib Combine With POF Versus POF in Gastric Cancer |
|
|
| Not yet recruiting | 2 | 116 | RoW | Apatinib, Study drug, POF | Fujian Cancer Hospital | Gastric Adenocarcinoma, Advanced Cancer | 12/21 | 12/23 | | |
NCT04769908: Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis |
|
|
| Recruiting | 2 | 40 | RoW | Systemic Chemotherapy, Lenvatinib, Sintilimab | Sun Yat-sen University | ICC | 12/21 | 12/21 | | |
CLIMB, NCT03698461: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab |
|
|
| Completed | 2 | 20 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin, Oxaliplatin, Levoleucovorin, 5-FU, 5-fluorouracil | Asan Medical Center, Hoffmann-La Roche | Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms | 12/21 | 10/23 | | |
NCT03567629: Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 130 | RoW | Irinotecan, fluorouracil / calcium folinate, Capecitabine, S1, Bevacizumab, Cetuximab, Oxaliplatin | Peking University, Liaoning Tumor Hospital & Institute, Zhejiang University | mCRC | 12/21 | 12/23 | | |
NCT04301557: PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | PD-1 Antibody, Toripalimab, Oxaliplatin, Capecitabine, External beam radiotherapy, Total mesorectal excision | Sun Yat-sen University | DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer | 04/24 | 12/24 | | |
NCT04466254: Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 75 | RoW | CPGJ602, cetuximab | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Metastatic Colorectal Cancer | 12/21 | 03/22 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
| Recruiting | 2 | 20 | Europe | Atezolizumab, MPDL3280A, Capecitabine, L01BC06, Oxaliplatin, L01XA03, Docetaxel, L01CD02 | The Netherlands Cancer Institute, Hoffmann-La Roche | Stomach Cancer, Gastro Esophageal Junction Cancer | 01/22 | 01/22 | | |
NCT04833036: c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI |
|
|
| Recruiting | 2 | 120 | RoW | Irinotecan, cetuximab | Fudan University | Colorectal Cancer | 01/22 | 11/22 | | |
NCT04003792: Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. |
|
|
| Recruiting | 2 | 49 | RoW | oxaliplatin, FOLFIRI Protocol, Bevacizumab | Rabin Medical Center | Liver Metastasis Colon Cancer | 01/22 | 01/22 | | |
| Active, not recruiting | 2 | 54 | Europe | Cannabidiol 100 MG/ML, CBD | Zealand University Hospital, University of Copenhagen | Chemotherapy-induced Peripheral Neuropathy | 01/22 | 08/23 | | |
NCT05029973: HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC |
|
|
| Recruiting | 2 | 30 | RoW | HAIC, Hepatic Artery Infusion Chemotherapy, FOLFOX, Sintilimab, IBI308, Bevacizumab Biosimilar, IBI305 | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 01/22 | 11/23 | | |
2021-000507-20: Study to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA. Estudio para evaluar el efecto de la quimioterapia adyuvante intensiva frente a la estándar en el cáncer de colon localizado con ADN tumoral circulante. |
|
|
| Not yet recruiting | 2 | 164 | Europe | Concentrate for solution for infusion, Powder and solution for solution for injection, Solution for injection/infusion, Film-coated tablet, Irinotecan, OXALIPLATIN, Calcium folinate, FLUORURACIL, Capecitabine | Instituto de Investigación Sanitaria INCLIVA, Instituto de Salud Carlos III | Localised Colon Cancer (stage II-III) Cáncer Colorrectal Localizado (estadio II-III), Colon Cancer (stage II-III) Cáncer Colorrectal (estadio II-III), Diseases [C] - Cancer [C04] | | | | |
NCT04890392: Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC |
|
|
| Recruiting | 2 | 20 | RoW | PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin) | Wuhan Union Hospital, China | Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma | 01/22 | 02/22 | | |
ZLK-XXY-1, NCT04202484: Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules | RenJi Hospital | Gastric Cancer | 02/22 | 02/23 | | |
2021-000150-26: Short-term chemotherapy plus pembrolizumab, followed by Pembrolizumab and Olaparib for patients with Her-2 negative gastric cancer–POLESTAR – |
|
|
| Not yet recruiting | 2 | 31 | Europe | Olaparib, Oxaliplatin, Calcium Folinate, 5-Fluorouracil, Capecitabine, MK-7339, Solution for infusion, Film-coated tablet, Solution for injection, KEYTRUDA (pembrolizumab, MK-3475) | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, MSD Sharp & Dohme GmbH | metastatic or advanced inoperable Her-2 negative esophagogastric adenocarcinoma, metastatic advanced gastric cancer, Diseases [C] - Cancer [C04] | | | | |
NCT06353581: Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX |
|
|
| Active, not recruiting | 2 | 78 | RoW | Neulapeg, Control | Yonsei University | Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | 05/24 | 05/24 | | |
NCT05997524: Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. |
|
|
| Completed | 2 | 60 | RoW | Trastuzumab, Oxaliplatin, Capecitabine | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Advanced Gastric Carcinoma | 02/22 | 06/23 | | |
NCT04891900: TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 25 | NA | TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine, PD-L1 inhibitor/Anlotinib | Henan Cancer Hospital | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 03/22 | 04/22 | | |
NCT05602935: Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study |
|
|
| Active, not recruiting | 2 | 29 | RoW | Camrelizumab, SOX, Surgery | The Second Affiliated Hospital of Fujian Medical University | Stomach Neoplasms, Digestive System Neoplasms, Neoplasms, Digestive System Diseases, Stomach Diseases, Neoplasms by Site | 03/22 | 12/26 | | |
NCT04354662: Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab, JS001, Docetaxel, Fluorouracil, Leucovorin, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 03/22 | 06/24 | | |
FOLRT, NCT05399394: Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 50 | NA | Chemotherapy, Induction therapy, Radiation | Campus Bio-Medico University | Pancreatic Cancer | 04/22 | 06/22 | | |
NCT05018182: FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 69 | RoW | Oxaliplatin, Eloxatin, Irinotecan, Campto, Folinic Acid, Leukovorin, 5FU, 5-Fluorouracil, Capecitabine, Xeloda | West China Hospital | High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy, FOLFOXIRI Regimen | 04/22 | 08/22 | | |
ACTRN12619000990123: A study to look at the safety and efficacy of Acalabrutinib and Rituximab followed by chemo with or without Autologous stem cell transplant (ASCT) and maintenance Acalabrutinib and Rituximab in fit patients with previously untreated mantle cell lymphoma. |
|
|
| Active, not recruiting | 2 | 44 | | | Australasian Leukaemia and Lymphoma Group, Acerta | Mantle cell Lymphoma | | | | |
NCT04411537: The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | PD-1 antibody, Capecitabine, Xeloda, Irinotecan, Neoadjuvant Radiotherapy | Fudan University | Locally Advanced Rectal Cancer | 04/22 | 12/22 | | |
NCT04411524: The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | PD-1 antibody, Capecitabine, Xeloda, Irinotecan, Neoadjuvant Radiotherapy | Fudan University | Locally Advanced Rectal Cancer | 04/22 | 12/22 | | |
NCT03878472: Neoadjuvant Immunotherapy for Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | SHR1210, Apatinib, S1, Oxaliplatin | Qilu Hospital of Shandong University | Gastric Cancer | 05/22 | 12/24 | | |
NCT04367025: Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer |
|
|
| Not yet recruiting | 2 | 70 | RoW | Camrelizumab, SHR-1210, Oxaliplatin, OXA, S1 | Chinese PLA General Hospital | Gastric Cancer | 05/22 | 05/23 | | |
ChiCTR2000032387: Prospectively Randomized Control Clinical Trial of neoadjuvant modified FOLOXIRI chemotherapy alone compared to neoadjuvant modified FOLFOX6 chemotherapy for locally advanced colon cancer in cT4b |
|
|
| Not yet recruiting | 2 | 208 | | neoadjuvant modified FOLOXIRI chemotherapy alone ;neoadjuvant modified FOLFOX6 chemotherapy alone | Third Affiliated Hospital, Kunming Medical University; Third Affiliated Hospital, Kunming Medical University, none | colon cancer | | | | |
ChiCTR2000032191: Prospectively Randomized Control Clinical Trial for Neoadjuvant Modified FOLOXIRI Chemotherapy Alone Compared to Neoadjuvant Modified FOLFOX6 Chemotherapy for cT3-T4NxM0 and MRF Positive Rectal Cancer |
|
|
| Recruiting | 2 | 308 | | neoadjuvant mFOLFOXIRI chemotherapy alone ;neoadjuvant mFOLFOX6 chemotherapy alone | Third Affiliated Hospital, Kunming Medical University; Third Affiliated Hospital, Kunming Medical University, self-raised | rectal cancer | | | | |
NCT04423965: A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC |
|
|
| Recruiting | 2 | 220 | RoW | mFOLFOXIRI, Chemoradiotherapy | First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Zhejiang Cancer Hospital | Locally Advanced Rectal Cancer | 05/22 | 05/25 | | |
NCT05003700: Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 48 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, Lenvima, Camrelizumab | Nanfang Hospital of Southern Medical University | Hepatocellular Carcinoma | 05/22 | 05/24 | | |
NCT03957564: Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation., Follow-up of DFS and OS in patients with gastric cancer after operation. | Affiliated Hospital of Qinghai University | Gastric Cancer, Gastro-oesophageal Junction Cancer | 05/22 | 05/24 | | |
NCT04341857: PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | PD-1 Monoclonal Antibody(Sintilimab) | Henan Cancer Hospital | Gastric and Esophagogastric Junction Adenocarcinoma | 05/22 | 07/22 | | |
SAMCO, NCT03186326: Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer |
|
|
| Active, not recruiting | 2 | 132 | Europe | FOLFOX regimen, FOLFIRI Protocol, Avelumab, Panitumumab, Cetuximab, Bevacizumab, Aflibercept | Federation Francophone de Cancerologie Digestive | Metastatic Colorectal Cancer, MSI | 05/22 | 05/23 | | |
NCT05066802: A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma |
|
|
| Recruiting | 2 | 27 | RoW | neoadjuvant modified FOLFIRINOX | Yonsei University | Resectable Pancreatic Adenocarcinoma | 05/22 | 05/23 | | |
NCT02635971: Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 168 | RoW | Transcatheter arterial infusion, Intravenous chemotherapy, Gemcitabine, Oxaliplatin | Fudan University | Carcinoma, Pancreatic | 06/22 | 12/22 | | |
NCT02954536: Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer |
|
|
| Completed | 2 | 37 | US | pembrolizumab, trastuzumab, capecitabine, cisplatin, Oxaliplatin, 5-Fluorouracil, 5-FU | Memorial Sloan Kettering Cancer Center | Esophageal Cancer, Gastric Cancer | 06/22 | 03/23 | | |
|
NCT03781323: Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 2 | 12 | US | FOLFOX | University of Rochester | Advanced Rectal Cancer | 06/22 | 06/27 | | |
NCT04508452: A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC |
|
|
| Recruiting | 2 | 91 | RoW | Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination | First Affiliated Hospital of Zhejiang University | Unresectable Metastatic Colorectal Carcinoma | 06/22 | 06/23 | | |
NCT05039944: SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies |
|
|
| Terminated | 2 | 7 | RoW | SI-B001, Irinotecan, FOLFIRI Protocol, FOLFOX Protocol | Sichuan Baili Pharmaceutical Co., Ltd. | Colorectal Cancer | 06/22 | 06/22 | | |
2021-002169-16: USE OF CIRCULATING TUMOR DNA TEST TO INTENSIFY POST-OPERATIVE TREATMENT OF PATIENTS WITH RESECTED COLON CANCER. UTILIZZO DEL DNA TUMORALE CIRCOLANTE PER INTENSIFICARE IL TRATTAMENTO POST-OPERATORIO DEI PAZIENTI CON TUMORE DEL COLON OPERATO. |
|
|
| Not yet recruiting | 2 | 459 | Europe | Calcio Levofolinato, Oxaliplatino, Capecitabina, Irinotecan, LONSURF, Fluorouracile, Lonsurf, [Calcio Levofolinato], [Oxaliplatino], [Capecitabina], [Irinotecan], [TAS-102], [Fluorouracile], Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Solution for injection/infusion, Solution for infusion, LONSURF - 15 MG/6,14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE, LONSURF - 20 MG/8,19 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE | Fondazione GONO, SERVIER ITALIA SPA, Servier Affaires Médicales, Fondazione GONO, Foundation Medicine Inc | STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS. TUMORE DEL COLON RESECATO IN STADIO III O IN STADIO II AD ALTO RISCHIO., RESECTED COLON CANCER Tumore del colon operato, Diseases [C] - Cancer [C04] | | | | |
NCT03549494: Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction |
|
|
| Completed | 2 | 45 | RoW | Ocoxin-Viusid® | Catalysis SL | Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms, Head and Neck Neoplasms, Gastrointestinal Disease, Digestive System Disease, Esophageal Diseases, Stomach Diseases, Esophagogastric Junction Disorder | 06/22 | 02/23 | | |
NCT01871571: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer |
|
|
| Active, not recruiting | 2 | 17 | US | bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI) | Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer | 06/22 | 06/23 | | |
NCT04250948: Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 108 | RoW | JS001, PD-1 antibody, Oxaliplatin, S1, Capecitabine, XELODA | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Locally Advanced Solid Tumor | 06/22 | 10/24 | | |
ChiCTR2000033070: A Multicenter, Open-Label, Single-Arm Phase II Trial to Evaluate the Efficacy and Safety of Capecitabine /Oxaliplatin (XELOX Regimen) in Combination with Regorafenib and PD-1 Monoclonal Antibody in First-line Treatment of Patients with HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 73 | | Capecitabine/Oxaliplatin (XELOX Regimen) in Combination with Regorafenib and PD-1 Monoclonal Antibody | Shanghai Oriental Hospital; Shanghai Oriental Hospital, East Clinical Center of Oncology, ECCO | HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | | | | |
NCT04631757: Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 33 | NA | Camrelizumab + SOX + Radiotherapy | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer | 06/22 | 12/23 | | |
NCT04627363: HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama |
|
|
| Not yet recruiting | 2 | 30 | NA | Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Bevacizumab, Liver Neoplasms, Toripalimab, Oxaliplatin | 06/22 | 06/23 | | |
| Recruiting | 2 | 67 | RoW | Camrelizumab combined with SOX/ or apatinib | First Affiliated Hospital Xi'an Jiaotong University, Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Gastric Cancer | 06/22 | 12/22 | | |
| Active, not recruiting | 2 | 270 | Europe | Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin | Ludwig-Maximilians - University of Munich | Metastatic Pancreatic Cancer | 07/22 | 07/23 | | |
NCT04324476: A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine | Jiangsu Cancer Institute & Hospital | Advanced Colorectal Cancer | 07/22 | 06/23 | | |
REPAN, NCT03940131: Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR |
|
|
| Recruiting | 2 | 30 | RoW | Panitumumab, Folfox, Folfiri | King Abdullah Medical City | Metastatic Colorectal Cancer | 07/22 | 07/22 | | |
NCT05036798: Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. |
|
|
| Active, not recruiting | 2 | 30 | RoW | Tislelizumab, Lenvatinib, Gemox | Tianjin Medical University Cancer Institute and Hospital | Potentially Resectable Locally Advanced Malignant Tumors of Biliary System | 07/22 | 12/23 | | |
NCT03563248: Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 168 | US | FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery | Massachusetts General Hospital, Bristol-Myers Squibb, Stand Up To Cancer, Lustgarten Foundation | Pancreatic Cancer | 07/22 | 06/27 | | |
| Active, not recruiting | 2 | 160 | Europe | Oxaliplatin, Oxaliplatin LBM | Institut du Cancer de Montpellier - Val d'Aurelle | Stage III Colon Cancer | 07/22 | 12/24 | | |
NCT04518852: TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC |
|
|
| Completed | 2 | 27 | RoW | TACE combined with sorafenib and PD-1 mAb | Sichuan Cancer Hospital and Research Institute | Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib, Molecular Mechanisms of Pharmacological Action, Liver Diseases, Antineoplastic Agents, Protein Kinase Inhibitors | 07/22 | 01/23 | | |
NCT03322969: Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy |
|
|
| Recruiting | 2 | 60 | RoW | Paclitaxel/DDP, Group A, XELOX/SOX, Group B | Peking Union Medical College Hospital | Locally Advanced Gastric Cancer | 08/22 | 08/23 | | |
NCT03126071: Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Raltitrexed, Irinotecan, Oxaliplatin, Bevacizumab, Avastin | Jiangsu Cancer Institute & Hospital | Advanced Colorectal Cancer | 08/22 | 02/23 | | |
NCT06163729: Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastroesophageal Junction Adenocarcinoma (Siewert II-III) | 05/25 | 05/28 | | |
NCT04994236: Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy |
|
|
| Recruiting | 2 | 49 | RoW | Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin), HAIC | Hui-Chuan Sun | Hepatocellular Carcinoma | 08/22 | 12/22 | | |
| Active, not recruiting | 2 | 150 | Canada, US | Folfirinox, Folinic Acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin, Gemcitabine/nab-paclitaxel | University Health Network, Toronto, Johns Hopkins University, Cold Spring Harbor Laboratory, Ontario Institute for Cancer Research, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Stand Up To Cancer | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer | 01/25 | 09/26 | | |
2022-000273-81: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy |
|
|
| Not yet recruiting | 2 | 118 | Europe | LONSURF, ELVORINE, Coated tablet, Solution for infusion, Capsule, LONSURF, ELOXATINE, FOLINATE DE CALCIUM, 5-Fluorouracil, capecitabine, ELVORINE | UNICANCER, Laboratoire SERVIER | Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy., Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04062058: A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 82 | RoW | SIB-IMRT, S-1, SOX, Surgery | Jing Jin, M.D., Beijing Hope Run | Gastric Cancer, Neoadjuvant Therapy | 09/22 | 09/23 | | |
2021-006512-87: Pembrolizumab and trastuzumab in combination with chemotherapy before and after surgery for patients with HER2-positive gastric cancer - PHERFLOT – |
|
|
| Not yet recruiting | 2 | 30 | Europe | Oxaliplatin, Folinic acid, 5-Fluorouracil, Docetaxel, Solution for infusion, Powder for solution for infusion, Solution for injection/infusion, Solution for injection, Concentrate for solution for infusion, KEYTRUDA® (Pembrolizumab, MK-3475), Ontruzant® (Trastuzumab, OG-9482) | Institut für Klinische Krebsforschung IKF GmbH, MSD Sharp & Dohme GmbH, ORGANON Healthcare GmbH | HER2 positive, localized esophagogastric adenocarcinoma, operable gastric cancer, Diseases [C] - Cancer [C04] | | | | |
QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | HAIC+TAE, Tislelizumab, Surufatinib | Qilu Hospital of Shandong University, BeiGene | Intrahepatic Cholangiocarcinoma | 05/24 | 12/25 | | |
NCT03271255: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) |
|
|
| Recruiting | 2 | 80 | RoW | Apatinib Mesylate Tablets, YN968D1, Bevacizumab Injection, Avastin | Shenzhen People's Hospital | Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms | 09/22 | 12/22 | | |
SUNRISE, NCT03714490: MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer |
|
|
| Recruiting | 2 | 200 | RoW | SCPRT, CRT, CAPOX, capecitabine, oxaliplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rectal Neoplasms | 09/24 | 09/25 | | |
NCT04119622: Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, oxaliplatin, capecitabine | Aiping Zhou | Gastric Cancer Stage II, Gastric Cancer Stage III | 09/22 | 10/24 | | |
ChiCTR2000037757: Clinical trial of PD-1 blockade after reduced-dose of oxaliplatin induction in neoadjuvant therapy for local advanced gastric cancer patient |
|
|
| Not yet recruiting | 2 | 60 | | reduced SOX+anti-PD-1 ;SOX | Shanghai General Hospital; Shanghai General Hospital, Sheng Kang Clinical Creative Three-year Program | Gastric Cancer | | | | |
NCT05254899: Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL |
|
|
| Recruiting | 2 | 54 | RoW | Anti-PD-1 monoclonal antibody, Tislelizumab, Pegaspargase, Gemcitabine, Oxaliplatin, Involved site radiotherapy | Chinese Academy of Medical Sciences, Beijing Cancer Hospital, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Jilin University | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer | 09/22 | 09/24 | | |